Opinion|Videos|October 7, 2024
Treatment Considerations for Patients With HER2+ NSCLC
Key Takeaways
- Clinicians must balance therapeutic benefits and risks, particularly concerning adverse events like interstitial lung disease, by tailoring treatment plans to individual patient needs.
- Evolving strategies to address resistance to HER2-directed therapies focus on understanding resistance mechanisms and developing novel agents or combination therapies.
Panelists discuss how clinicians carefully weigh the efficacy of HER2-directed therapies against their safety profiles, particularly focusing on managing serious adverse events like interstitial lung disease, while also considering emerging strategies to combat resistance to these treatments as research in the field progresses.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do clinicians balance the efficacy and safety profiles of these therapies, particularly considering adverse events like interstitial lung disease?
- (Bazhenova) How might strategies to address resistance to HER2-directed therapies evolve with ongoing research?
Advertisement
Related to this article
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.
At an AJMC Stakeholder Interchange in Houston, leukemia specialists from academic centers and community practices said menin inhibitors work best in combination, warned that differentiation syndrome can strike months into therapy, and described payer rules that delay access even at flagship centers.
UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.
At an AJMC® Stakeholder Interchange in New York, New York, leukemia specialists agreed that menin inhibitors fill a real gap in relapsed/refractory acute myeloid leukemia, but said that slow molecular testing, formulary rules, and thin community infrastructure still determine which patients get them and how fast.
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
Advertisement
Advertisement
Trending on AJMC
1
At the Pharmacy, Affordability Connects Policy, Plans, and Patients
2
Olanzapine/Samidorphan Tied to Longer Persistence in Schizophrenia
3
Retatrutide Tops Semaglutide on A1C, Weight in Head-to-Head Trial
4
UAB Works to Deliver Cutting-Edge Cancer Therapies, Reach Every Patient
5